Equity Overview
Price & Market Data
Price: $0.037
Daily Change: +$0.009 / 24.32%
Range: $0.02 - $0.04
Market Cap: $2,048,549
Volume: 411,204
Performance Metrics
1 Week: -6.35%
1 Month: -20.23%
3 Months: 174.5%
6 Months: -97.23%
1 Year: -98.61%
YTD: -96.36%
Company Details
Employees: 94
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. On February 10, 2025, Omega Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.